Physiomics plc

("Physiomics" or the "Company")

Director Dealing

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Ian Bagnall, Director of the Company, has acquired, via market purchases, 1,111,111 new ordinary shares of 0.4p in the Company ("Ordinary Shares") at a price of 0.45p per Ordinary Share.

Accordingly, Mr Bagnall's total holding in the Company will be 16,111,111 Ordinary Shares, representing approximately 3.55% of the Company's issued share capital.

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc **Email: info@physiomics.co.uk**

Mike Whitlow

Strand Hanson Ltd (NOMAD and Broker) **Tel: +44 (0) 20 7409 3494**

James Dance & James Bellman

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

PDMR Notification Form:

The notification below, which has been made in accordance with the requirements of UK MAR, provides further details.

1.	**Details of the person discharging managerial responsibilities / person closely associated**	
a)	Name	Ian Bagnall
2.	**Reason for the Notification**	
a)	Position/status	Executive Director
b)	Initial notification/amendment	Initial notification

3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Physiomics plc
b)	LEI	213800A71DSZ6ABMTQ91
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted**	
a)	Description of the Financial instrument, type of instrument	Purchase of Ordinary Shares
	Identification code	GB00BDR6W943
b)	Nature of the Transaction	Purchase of new Ordinary Shares
c)	Price(s) and volume(s)	Price(s): £0.0045 Volume(s): 1,111,111
d)	Aggregated information Aggregated volume Price	N/A (Single transaction)
e)	Date of the transaction	10 July 2026
f)	Place of the transaction	London Stock Exchange